NeuroPace, Inc.
NASDAQ:NPCEMedical - Devices
Healthcare
$8.14 +0.30%
+$0.05 today
- Market cap
- $280.44M
- Beta
- 1.88
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.64
52W Low $7.56High $19.60
Volume 0.35M
Average 0.18M
Income Statement
Follow revenue through to earnings.
Revenue
$99.99M
FY 2025 · Annual
+25.1% YoYOperating Income
-$16.34M
FY 2025 · Annual
Net Income
-$21.46M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 45.18M | 45.52M | 65.42M | 79.91M | 99.99M |
| Cost of Revenue | 11.75M | 13.03M | 17.3M | 20.82M | 22.77M |
| Gross Profit | 33.44M | 32.49M | 48.12M | 59.09M | 77.22M |
| Gross Margin | 74.0% | 71.4% | 73.6% | 73.9% | 77.2% |
| Research & Development | 18.21M | 21.95M | 20.78M | 23.65M | 27.89M |
| Selling, General & Admin | 38.96M | 51.34M | 54.52M | 57.1M | 65.67M |
| Operating Expenses | 57.17M | 73.29M | 75.3M | 80.76M | 93.56M |
| Depreciation & Amortization | 296K | 2.99M | 1.61M | 1.77M | 1.95M |
| EBITDA | (28.37M) | (36.57M) | (22.83M) | (16.57M) | (12.06M) |
| EBITDA Margin | -62.8% | -80.3% | -34.9% | -20.7% | -12.1% |
| Operating Income | (23.74M) | (40.79M) | (27.17M) | (21.67M) | (16.34M) |
| Operating Margin | -52.5% | -89.6% | -41.5% | -27.1% | -16.3% |
| Interest Income | 448K | 1.58M | 3.05M | 3.02M | 2.82M |
| Interest Expense | 7.41M | 7.53M | 8.52M | 8.8M | 7.46M |
| Other Income / Expenses | (12.34M) | (6.29M) | (5.78M) | (5.47M) | (5.13M) |
| Income Before Tax | (36.08M) | (47.08M) | (32.96M) | (27.14M) | (21.47M) |
| Pre-Tax Margin | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (36.08M) | (47.08M) | (32.96M) | (27.14M) | (21.47M) |
| Net Margin | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |
| EPS (Basic) | (2.17) | (1.91) | (1.27) | (0.93) | (0.66) |
| EPS (Diluted) | (2.17) | (1.91) | (1.27) | (0.93) | (0.66) |
| 16.61M | 24.59M | 25.85M | 29.13M | 32.72M | |
| 16.61M | 24.59M | 25.85M | 29.13M | 32.72M |
NPCE Earnings Waterfall · TTM
NASDAQ:NPCE · Revenue to Net Income
Key Ratios
EPS$-0.65
Gross Margin78.4%
Net Margin-22.5%
P/E Ratio-24.5
P/S Ratio16.8
Analysis
$99.5M of revenue converted into -$21.6M of net income for the selected period. Gross margin is 78.4% and net margin is -22.5%, showing how much revenue survives after costs and taxes. EPS is $-0.65, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 25, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 21, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 4, 2026 |
How much revenue does NPCE generate?
NeuroPace, Inc. (NPCE) reported $99.99M of revenue in fiscal 2025.
Is NPCE profitable?
NeuroPace, Inc. (NPCE) reported -$21.46M of net income, with a net margin of -21.5%.
Continue the stock analysis
Jump to another research area for this company.